Effect of the peptides Relaxin, Neuregulin, Ghrelin and Glucagon-like peptide-1, on cardiomyocyte factors involved in the molecular mechanisms leading to diastolic dysfunction and/or heart failure with preserved ejection fraction
- PMID: 29807087
- DOI: 10.1016/j.peptides.2018.05.009
Effect of the peptides Relaxin, Neuregulin, Ghrelin and Glucagon-like peptide-1, on cardiomyocyte factors involved in the molecular mechanisms leading to diastolic dysfunction and/or heart failure with preserved ejection fraction
Abstract
Heart failure with preserved ejection fraction (HFpEF) represents an important cardiac condition because of its increasing prevalence, resistance to treatment and high associated morbidity and mortality. Two of the major mechanisms responsible for HFpEF are impaired cardiomyocyte sarcoplasmic reticulum (SR) Ca2+ ATPase (SERCA2a), which is responsible for calcium reuptake into the SR, and cardiac fibroblasts/myofibroblasts that produce collagen or myocardial fibrosis. Phospholamban (PLB), in the SR and endoplasmic reticulum, is the primary regulator of SERCA2a in the heart and acts as a reversible inhibitor of SERCA2a. Glucagon-like peptide-1, a 30 amino acid peptide, improves diastolic function through increasing SERCA2a expression and activity as well as by decreasing phosphorylation of Ryanodine receptors. It also enhances collagen production through enhanced procollagen IalphaI/IIIalphaI, connective tissue growth factor, fibronectin, TGF-β3 as well as Interleukin -10, -1beta, and -6 gene expression. Relaxin-2, a two chain, 53 amino acid peptide, increases Ser16- and Thr17-phosphorylation levels of PLB, thereby relieving SERCA2a of its inhibition. H3 Relaxin inhibits TGF-β1-stimulated collagen deposition through H3 relaxin-induced increases in pSmad2. Neuregulin-1, an epidermal growth factor, induces nitric oxide and PI-3 kinase activation that enhance SERCA2 activity. Neuregulin-1 was associated with less myocardial macrophage infiltration and cytokine expression reducing collagen deposition. Ghrelin, a 28 amino acid peptide, improves SERCA2a function by inducing PLB phosphorylation. Ghrelin also reduces cardiac fibrosis. In summary, Glucagon-like peptide-1, Relaxin-2, Neuregulin-1, and Ghrelin each modify calcium dynamics, collagen expression, and myocardial fibrosis through attenuation of deleterious signaling cascades, and induction of adaptive pathways, representing potential therapeutic targets for HFpEF.
Keywords: Ghrelin; Glucagon-like peptide-1; Heart failure with preserved ejection fraction (HFpEF); Myocardial fibrosis; Neuregulin-1; Relaxin-2; SR Ca(2+) ATPase.
Copyright © 2018 Elsevier Inc. All rights reserved.
Similar articles
-
Early calcium handling imbalance in pressure overload-induced heart failure with nearly normal left ventricular ejection fraction.Biochim Biophys Acta Mol Basis Dis. 2019 Jan;1865(1):230-242. doi: 10.1016/j.bbadis.2018.08.005. Epub 2018 Aug 4. Biochim Biophys Acta Mol Basis Dis. 2019. PMID: 30463691
-
Remodelling of cAMP dynamics within the SERCA2a microdomain in heart failure with preserved ejection fraction caused by obesity and type 2 diabetes.Cardiovasc Res. 2024 Mar 14;120(3):273-285. doi: 10.1093/cvr/cvad178. Cardiovasc Res. 2024. PMID: 38099489 Free PMC article.
-
Resveratrol protects against lipopolysaccharide-induced cardiac dysfunction by enhancing SERCA2a activity through promoting the phospholamban oligomerization.Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H1051-H1062. doi: 10.1152/ajpheart.00296.2016. Epub 2016 Sep 2. Am J Physiol Heart Circ Physiol. 2016. PMID: 27591219
-
Sarcoplasmic reticulum Ca2+-ATPase modulates cardiac contraction and relaxation.Cardiovasc Res. 2003 Jan;57(1):20-7. doi: 10.1016/s0008-6363(02)00694-6. Cardiovasc Res. 2003. PMID: 12504810 Review.
-
Role of oxidants on calcium and sodium movement in healthy and diseased cardiac myocytes.Free Radic Biol Med. 2013 Oct;63:338-49. doi: 10.1016/j.freeradbiomed.2013.05.035. Epub 2013 Jun 1. Free Radic Biol Med. 2013. PMID: 23732518 Review.
Cited by
-
Regional Differences in the Ghrelin-Growth Hormone Secretagogue Receptor Signalling System in Human Heart Disease.CJC Open. 2020 Nov 4;3(2):182-194. doi: 10.1016/j.cjco.2020.10.015. eCollection 2021 Feb. CJC Open. 2020. PMID: 33644732 Free PMC article.
-
Heal the heart through gut (hormone) ghrelin: a potential player to combat heart failure.Heart Fail Rev. 2021 Mar;26(2):417-435. doi: 10.1007/s10741-020-10032-2. Epub 2020 Oct 6. Heart Fail Rev. 2021. PMID: 33025414 Review.
-
Liraglutide suppresses atrial electrophysiological changes.Heart Vessels. 2019 Aug;34(8):1389-1393. doi: 10.1007/s00380-018-01327-4. Epub 2019 Feb 14. Heart Vessels. 2019. PMID: 30762094
-
Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction.J Diabetes Res. 2021 Mar 27;2021:8838026. doi: 10.1155/2021/8838026. eCollection 2021. J Diabetes Res. 2021. PMID: 33855087 Free PMC article.
-
Cardiomyocyte Damage: Ferroptosis Relation to Ischemia-Reperfusion Injury and Future Treatment Options.Int J Mol Sci. 2023 Aug 16;24(16):12846. doi: 10.3390/ijms241612846. Int J Mol Sci. 2023. PMID: 37629039 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous